Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

Atkinson, Sarah; L. Lubaczewski, Shannon; Ramaker, Sara; D. England, Richard; Wajsbrot, Dalia; Abbas, Richat; L. Findling, Robert

doi:10.1089/cap.2017.0099

Public

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

Published in Journal of Child and Adolescent Psychopharmacology • Nov 29, 2017

Authors:

Sarah Atkinson

Shannon L. Lubaczewski

Sara Ramaker

Abstract

OBJECTIVE: To evaluate the short-term efficacy and safety of desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder (MDD). METHODS: Outpatient children (7-11 years) and adolescents (12-17 years) who met DSM-IV-TR criteria for MDD and had screening a...

Subject

Placebo

Major depressive disorder

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!